Virpax Pharmaceuticals
Virpax Pharmaceuticals specializes in developing novel and proprietary drug-delivery systems across various pain and CNS disorder indications to enhance compliance and to optimize the efficacy of each product candidate. Our transforming drug-delivery platforms and their targeted drug-releasing capabilities have been developed to optimize the efficacy of our non-addictive pain management pipeline and our CNS disorder pipeline. Our goal is for each product candidate to become the standard of care in their respective Therapeutic sectors. Our business objective is to commercialize products that will be supported by respective medical societies, and advocacy groups, as well as be regarded by insurance companies, prescribers, pharmacists and hospitals. Optimizing Non-Addictive Drug Delivery Worldwide.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
Welcome
Virpax® Pharmaceuticals (Nasdaq: VRPX) is a publicly held emerging growth company located in Berwyn, PA and is focused on advancing the development and worldwide commercialization of its non-addictive pain and neurological disorder pipeline.
About Us
REINVENTING HOW HEALTHCARE PROFESSIONALS AND PATIENTS MANAGE PAIN
Pain is a universal condition, while the perception of pain is unique. Virpax Pharmaceuticals is committed to developing non-addictive product candidates that manage pain and its complexities, while providing treatment options and minimizing risks to patients and society. By combining selected drug compounds with our cutting-edge delivery systems, we strive to maximize our products’ capabilities and successfully bring them to market. We believe our proprietary delivery systems will reinvent how patients and prescribers manage pain worldwide.
NON-ADDICTIVE PRODUCTS
We are advancing drug development strategies that will address the prominent need for non-addictive alternatives in treatment of pain and CNS disorders. Our Molecular Envelope Technology (MET), topical spray film technology, and liposomal hydrogel technology will significantly improve our drug delivery characteristics by directly targeting pain symptoms and CNS Disorder symptoms at their source.
CNS GROWTH OPPORTUNITIES
Our MET platform is being used to grow our Central Nervous System (CNS) disorder pipeline. These additional patented formulations may include neurotransmission and neuroprotective actives. The current product candidates include Post Traumatic Stress Disorder (PTSD), and Rare Pediatric Epilepsy. In the future, the MET will be used to deliver actives that will be developed to manage other neurodegenerative disorders.
AREAS OF FOCUS
We are continuously strengthening our worldwide patents in the development of non-addictive treatments for pain and degenerative neurological disorders.
We are seeking FDA approval for a robust pipeline of product candidates that will radically change how clinicians prescribe pain and CNS disorder therapies in the future.